Kura Oncology to Report Second Quarter 2016 Financial Results
August 03, 2016 07:30 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced it will report second quarter 2016 financial...
Kura Oncology Doses First Patient in Phase 2 Study of Tipifarnib in Lower Risk Myelodysplastic Syndromes
June 16, 2016 17:30 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., June 16, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced the first patient has been dosed in a Phase 2...
Kura Oncology to Participate in the 2016 JMP Life Sciences Conference
June 14, 2016 07:30 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., June 14, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced its participation in the 2016 JMP Life Sciences...
Kura Oncology Reports Fourth Quarter and Full Year 2015 Operational and Financial Results
March 17, 2016 16:05 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., March 17, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc., (NASDAQ:KURA) a clinical stage biopharmaceutical company, today announced highlights and financial results for the fourth...
Kura Oncology to Report Fourth Quarter and Full Year 2015 Financial Results
March 11, 2016 07:30 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., March 11, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that it will report fourth quarter and full year...
Kura Oncology Announces Data Presentation on Lead Product Candidate Tipifarnib at the Upcoming ASH Meeting
December 03, 2015 07:00 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., Dec. 3, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that new data from a Phase 3 trial of tipifarnib, the...
Kura Oncology to Present at the Oppenheimer 2015 Healthcare Conference
December 01, 2015 07:00 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., Dec. 1, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that Troy Wilson, Ph.D., J.D., President and Chief...
Kura Oncology to Present at Upcoming Investor Conference
November 30, 2015 18:40 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., Nov. 30, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that Troy Wilson, Ph.D., J.D., President and Chief...
Kura Oncology Announces First Patient Dosed in an Investigator-Sponsored Phase 2 Trial of Tipifarnib in Patients With HRAS Mutant Urothelial Cancer
November 30, 2015 07:00 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., Nov. 30, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), today announced that the first patient has been dosed in an investigator-sponsored Phase 2 trial of its lead drug...
Kura Oncology to Present at the Jefferies 2015 Global Healthcare Conference
November 11, 2015 07:30 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., Nov. 11, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that Troy Wilson, Ph.D., J.D., President and Chief...